Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib + venetoclax versus obinutuzumab + chlorambucil in previously untreated CLL/SLL
NL-OMON54563Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ibrutinib, venetoclax, obinutuzumab, chlorambucil in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Janssen Pharmaceutical. Started May 2018; status: recruiting.
02
Drugs
ibrutinibvenetoclaxobinutuzumabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON54563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54563.